Endo raises FY21 adjusted EPS view to $1.95-$2.30 from $1.80-$2.30 » 16:3805/0605/06/21
FY21 consensus $2.11.…
FY21 consensus $2.11. Raises FY21 revenue view to $2.65B-$2.79B from $2.55B-$2.79B, consensus $2.7B.
Endo reports Q1 adjusted cont ops EPS 73c, consensus 48c » 16:3505/0605/06/21
Reports Q1 revenue…
Reports Q1 revenue $717.92M, consensus $668.65M.
|Over a week ago|
Endo names Mark Barberio Chairman of Board of Directors » 16:1804/2704/27/21
Endo International announced that Mark Barberio, who currently serves as an independent member of Endo's Board of Directors, has been appointed Chairman of the Board effective at the company's 2021 Annual General Meeting. Mr. Barberio's appointment is part of Endo's ongoing Board succession process, which has also included adding two new Board members since the company's 2020 Annual General Meeting. In addition, Paul Campanelli, who has served as Chairman of the Board since 2019 and who served as President and CEO from 2016 to 2020, will retire from the Board upon the expiration of his current term at the company's 2021 Annual General Meeting. Finally, Roger Kimmel, who has been Senior Independent Director since 2019 and who served as Chairman of the Board from 2014 to 2019, will also retire from the Board upon the expiration of his current term.
California lawyer accuses drugmakers of causing opioid addiction, WSJ reports » 06:2504/2004/20/21
JNJ, TEVA, ENDP, ABBV
A lawyer for several…
A lawyer for several California communities has accused Johnson & Johnson (JNJ), Teva (TEVA), Endo (ENDP), and AbbVie (ABBV) of causing a large wave of opioid addiction due to their aggressive marketing for pain pills, Sara Randazzo of The Wall Street Journal reports. The month long California trial, expected to start in May, could spur drugmakers to finalize settlements, with three large distributors and J&J already having proposed to pay a collective $26B to settle the case. Reference Link
Results in Endo's phase 3 study show meaningful improvement in severe cellulite » 16:1904/1304/13/21
The company states:…
The company states: "Endo International announced that Phase 3 data evaluating Qwo, or collagenase clostridium histolyticum-aaes for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery. In addition to Phase 3 studies, the publication also includes a supplemental video that demonstrates the injection techniques for QWO. The Phase 3 studies, conducted from February 2018 to September 2018, demonstrated that QWO provides a clinically meaningful improvement in the appearance of moderate to severe cellulite in the buttocks of adult women compared to placebo. QWO received FDA approval in July 2020 and is the first and only injectable treatment for moderate to severe cellulite in the buttocks of adult women."
|Over a month ago|
Endo comments on default liability judgment in Tennessee State court case » 09:2604/0704/07/21
Endo announced the entry…
Endo announced the entry of an order granting a default judgment on liability against its wholly-owned subsidiaries Endo Health Solutions and Endo Pharmaceuticals in Staubus, et al. v. Purdue Pharma, L.P., et al., which has been pending in the Circuit Court at Kingsport, Tennessee since 2017. The Staubus case involves allegations by three Tennessee District Attorneys General and an individual plaintiff that EHSI's and EPI's sale of prescription opioid medications violated Tennessee's Drug Dealer Liability Act. In December, the Tennessee Supreme Court unanimously ruled that Tennessee's District Attorneys General do not have standing to bring claims under the DDLA. On April 5, the Staubus court permitted several Tennessee counties to substitute into the case in place of the District Attorney General plaintiffs. On April 6, the Staubus court entered a default judgment against Endo on liability as a sanction for alleged discovery improprieties. The order does not address the issue of damages, which the Staubus court ordered to be tried at a future date. Endo has made efforts to address the Staubus court's concerns, including by hiring an additional law firm, producing additional documents and offering additional depositions at Endo's expense. Endo "strongly disagrees" with the Staubus court's orders and will seek review of the Staubus court's orders by the Tennessee appellate courts.
Endo transferred with a Sector Perform at RBC Capital » 16:5004/0604/06/21
RBC Capital transferred…
RBC Capital transferred coverage of Endo to analyst Daniel Busby, and kept a Sector Perform rating and $7 price target on the stock.
Endo price target raised to $7 from $6 at Barclays » 09:0103/0803/08/21
Barclays analyst Balaji…
Barclays analyst Balaji Prasad raised the firm's price target on Endo to $7 from $6 and keeps an Equal Weight rating on the shares. After holding an expert panel with two dermatologists to discuss the cellulite treatment landscape and potential for Endo's Qwo, the analyst is positive on the upcoming launch. The experts noted optimal Qwo pricing was very important for uptake, as consumers were unlikely to spend thousands of dollars on cellulite treatment, Prasad tells investors in a research note.
Endo price target lowered to $10 from $11 at Citi » 06:2803/0403/04/21
Citi analyst Navann Ty…
Citi analyst Navann Ty lowered the firm's price target on Endo to $10 from $11 and keeps a Buy rating on the shares. The stock dropped significantly after releasing "strong" fiscal 2020 earnings, driven by a lower than expected 2021 outlook, Ty tells investors in a research note. The analyst sill has a positive view of Qwo and Biospecifics, potential for a lower than expected opioid settlement and Novavax upside.
JPMorgan to hold a virtual conference » 04:5503/0303/03/21
ASGN, EBS, CEQP, TTMI, SM, SVRGF, TLGHY, ENDP, MD, BZH, CENT, IT
Global High Yield &…
Global High Yield & Leveraged Finance Virtual Conference will be held on March 1-3.